Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"CANbridge Pharmaceuticals","sponsor":"3W Fund Management","pharmaFlowCategory":"D","amount":"$43.0 million","upfrontCash":"Undisclosed","newsHeadline":"Canbridge Pharmaceuticals Completes $43 Million Series E Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Approval of CAN108for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CANbridge Pharmaceuticals"},{"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN108 New Drug Application\/Orphan Drug Registration (NDA\/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CANbridge Pharmaceuticals"}]

CANbridge Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

Details:

LIVMARLI™ (maralixibat) is a barely absorbed ileal bile acid transporter (IBAT) inhibitor that blocks the enterohepatic circulation of bile acids, reduces bile acid levels in the liver and serum, reduces the resultant liver injury and relieves pruritus.

Lead Product(s): Maralixibat

Therapeutic Area: Genetic Disease Product Name: Livmarli

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Mirum Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 28, 2022

ASK
US

Upload
your Pipeline Activity

CANbridge Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CANbridge Announces Approval of CAN108for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Touri...

Details:

Livmarli (maralixibat), barely absorbed IBAT inhibitor has been approved under early and pilot implementation policy in boao lecheng , which will allow it to be imported and used as an urgently needed drug in the region for treatment of ALGS.

Lead Product(s): Maralixibat

Therapeutic Area: Genetic Disease Product Name: Livmarli

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 25, 2022

ASK
US

Upload
your Pipeline Activity

CANbridge Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Canbridge Pharmaceuticals Completes $43 Million Series E Financing

Details:

The proceeds will be used to expand the CANbridge rare disease pipeline through internal development and external partnerships, accelerate the clinical development of pre-clinical stage assets, prepare the commercial launch of Hunterase® and supplement working capital.

Lead Product(s): Idursulfase beta

Therapeutic Area: Genetic Disease Product Name: Hunterase

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: 3W Fund Management

Deal Size: $43.0 million Upfront Cash: Undisclosed

Deal Type: Series E Financing December 01, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY